North East and North Cumbria Formulary


	North East and North Cumbria ICS Formulary

Search

Recent Updates - Updated items

All Formulary Amendments

Records 1 to 30 of 46

Older

Oldest

Details
LDL	Link Added : MHRA Drug Safety Update (Dec 2021): Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS) : https://www.gov.uk/drug-safety-update/venetoclax-venclyxtov-updated-recommendations-on-tumour-lysis-syndrome-tls	14/07/2023 13:15:34 (dmcdermott )
LDL	Link Added : NICE TA862: HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments : https://www.nice.org.uk/guidance/ta862	09/07/2023 21:04:50 (dmcdermott )
LDL	Link Added : NICE TA663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia : https://www.nice.org.uk/guidance/ta663	04/07/2023 15:39:54 (rpaylor )
UPD	sitematrix Changed from 0 to	27/07/2022 15:36:25 (DavidS )
UPD	BlueTeq Changed from N to Y	27/07/2022 15:36:25 (DavidS )
UPD	Venetoclax (Venclyxto^®) updated	27/07/2022 15:36:25 (DavidS )
UPD	Published from Draft Mode	27/07/2022 14:26:54 (LoweryM )
UPD	sitematrix Changed from 0 to	27/07/2022 14:26:51 (LoweryM )
UPD	Venetoclax (Venclyxto^®) approved	27/07/2022 14:26:51 (LoweryM )
LDL	Link 19207 Deleted : 08.01.05 : https://www.gov.uk/government/uploads/system/uploads/attachment data/file/547406/EAMS Public Assessment Report - Venetoclax.pdf	27/07/2022 14:24:43 (DavidS )
UPD	sitematrix Changed from 0 to	27/07/2022 14:24:30 (DavidS )
UPD	FurtherInformation Changed from Approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutations, and who are unsuitable for or have failed a B-cell receptor pathwa	27/07/2022 14:24:30 (DavidS )
UPD	Venetoclax (Venclyxto^®) updated	27/07/2022 14:24:30 (DavidS )
UPD	sitematrix Changed from 0 to	15/07/2022 09:24:05 (DavidS )
UPD	Venetoclax (Venclyxto^®) updated	15/07/2022 09:24:05 (DavidS )
LUP	Section link 19598 Updated: 08.01.05 : NICE TA796: Venetoclax for treating chronic lymphocytic leukaemia : https://www.nice.org.uk/guidance/ta796...	14/07/2022 15:34:38 (DavidS )
UPD	sitematrix Changed from 0 to	14/07/2022 15:34:23 (DavidS )
UPD	FurtherInformation Changed from Approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutations, and who are unsuitable for or have failed a B-cell receptor pathwa	14/07/2022 15:34:23 (DavidS )
UPD	Venetoclax NICE TA796	14/07/2022 15:34:23 (DavidS )
LDL	Link Added : NIC TA796: Venetoclax for treating chronic lymphocytic leukaemia : https://www.nice.org.uk/guidance/ta796	14/07/2022 15:33:38 (DavidS )
LDL	Link Added : NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable : https://www.nice.org.uk/guidance/ta787	14/07/2022 15:33:03 (DavidS )
UPD	sitematrix Changed from 0 to	14/07/2022 15:32:02 (DavidS )
UPD	isDraft Changed from N to Y	14/07/2022 15:32:02 (DavidS )
UPD	FurtherInformation Changed from Approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutations, and who are unsuitable for or have failed a B-cell receptor pat	14/07/2022 15:32:02 (DavidS )
UPD	Venetoclax NICE TA787	14/07/2022 15:32:02 (DavidS )
UPD	Published from Draft Mode	12/05/2022 11:03:56 (DavidS )
LDL	Link Added : NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable : https://www.nice.org.uk/guidance/ta765	26/04/2022 12:03:31 (DavidS )
UPD	sitematrix Changed from 0 to	26/04/2022 12:03:04 (DavidS )
UPD	isDraft Changed from N to Y	26/04/2022 12:03:04 (DavidS )
UPD	FurtherInformation Changed from Approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutations, and who are unsuitable for or have failed a B	26/04/2022 12:03:04 (DavidS )